Compare KRYS & MOH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | KRYS | MOH |
|---|---|---|
| Founded | 2015 | 1980 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 7.8B | 8.9B |
| IPO Year | 2017 | 2002 |
| Metric | KRYS | MOH |
|---|---|---|
| Price | $262.33 | $142.06 |
| Analyst Decision | Strong Buy | Hold |
| Analyst Count | 11 | 14 |
| Target Price | ★ $297.60 | $157.15 |
| AVG Volume (30 Days) | 217.1K | ★ 1.2M |
| Earning Date | 05-05-2026 | 04-22-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 128.00 | N/A |
| EPS | 6.84 | ★ 8.92 |
| Revenue | $389,130,000.00 | ★ $45,426,000,000.00 |
| Revenue This Year | $39.88 | $2.36 |
| Revenue Next Year | $34.38 | $5.23 |
| P/E Ratio | $38.23 | ★ $16.04 |
| Revenue Growth | ★ 33.94 | 11.75 |
| 52 Week Low | $123.03 | $121.06 |
| 52 Week High | $298.30 | $351.95 |
| Indicator | KRYS | MOH |
|---|---|---|
| Relative Strength Index (RSI) | 55.55 | 49.15 |
| Support Level | $251.93 | $140.20 |
| Resistance Level | $293.60 | $154.38 |
| Average True Range (ATR) | 9.28 | 6.63 |
| MACD | 2.05 | 0.87 |
| Stochastic Oscillator | 90.05 | 54.26 |
Krystal Biotech Inc is engaged in the healthcare sector in the United States. It is focused on the development of easy-to-use, redosable gene therapies to improve the lives of patients living with debilitating diseases. The company used its proprietary gene therapy platform, STAR-D to develop treatments for rare or orphan dermatological indications caused by the absence of or a mutation in a single gene. It plans to leverage its platform to expand its pipeline to include other dermatological indications in the future. The company has one operating segment, which is the business of developing and commercializing pharmaceutical products.
Molina provides medical insurance plans through Medicaid, the individual exchanges, and Medicare. It manages health benefit risks for more than 5 million people, with more than 85% of those members coming through contracts with state governments for their Medicaid programs. Medicaid contracts in just four states—California, New York, Texas, and Washington—account for over half of its enrollees.